1003P - Treatment outcomes and prognostic factors in Mexican patients with endometrial carcinoma: the Latin American experience

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Endometrial Cancer
Presenter Christian Flores-Balcázar
Authors C.H. Flores-Balcázar1, A. Alvarado-Zermeño2, M. Blake-Cerda2, A. Mota-García2, A. Poitevin-Chacón3, S. Rosales-Pérez4, G. Trejo-Duran2
  • 1Radioterapia, Instituto Nacional de Cancerologia, 14080 - Mexico City/MX
  • 2Radioterapia, Instituto Nacional de Cancerelogía, 14080 - Mexico City/MX
  • 3Radioterapia, Hospital Medica Sur, 14050 - Mexico City/MX
  • 4Radiation Oncology. Consultorio 330, Instituto Mexicano del Seguro Social, 06725 - Mexico City/MX



To analyze the clinical characteristics and treatment outcomes in patients with endometrial carcinoma treated in a Latin American institute with emphasis on patients receiving radiotherapy and chemotherapy after surgery.


A total of 412 patients with endometrial carcinoma admitted to our hospital between 1999 and 2008 were evaluated retrospectively. The mean age was 55 years (28-87). Two hundred seventy patients received RT following surgery. Stage distribution was as follows: 221 patients (54%) stage I, 86 patients (21%) stage II, and 103 patients (24.5%) stage III and 2 patients (0.5%) stage IVA.


Overall survival rate was 95% at 2 years, 84% at 5 years and 79% at 10 years. By the end of follow up, 338 patients (82%) were disease-free, and 13 (3%) were alive with disease. Univariate and multivariate analyses identified age, grade, serosal and adnexial involvement as significant predictors for overall survival.


The results of our study suggests that early stage, low-grade endometrial cancer with no risk factors should not receive external beam radiotherapy, intermediate risk patients should receive only vaginal vault brachytherapy and the use of chemotherapy with radiotherapy for patients high risk and advanced stage carcinoma the addition of radiotherapy is associated with a better survival being an effective therapeutic option. To our knowledge this is the largest series exploring the characteristics of Mexican patients treated for endometrial carcinoma in literature. We conclude that adjuvant radiotherapy should be considered an integral component of definitive treatment for women with unfavorable disease as a mean to decrease mortality and improve patient outcome.


All authors have declared no conflicts of interest.